NDAOTICSOLUTION/DROPS
Approved
Feb 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIDESILON is a fixed-dose combination of glacial acetic acid and desonide, a low-potency corticosteroid, formulated as an otic solution for topical ear administration. It is indicated for the treatment of acute otitis externa and other otic inflammatory conditions. The acetic acid provides antimicrobial properties while desonide reduces inflammation in the external auditory canal.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team is likely focused on defensive positioning and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIDESILON offers limited career expansion opportunities given zero linked job postings and an LOE-approaching lifecycle. Roles on this product emphasize cost management, market retention, and operational efficiency rather than innovation or market building.
Brand ManagerField Sales Representative
Worked on TRIDESILON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.